PATENT CLAIM ANALYSIS

Application Number: 15742725
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-12
Patent Classification: ["514", "391000"]

Abstract:
Presently disclosed are methods of treating cancer comprising administering a MEK inhibitor in combination with a proteasome inhibitor. In some embodiment, the cancer is a solid tumor. In some instances, the cancer has at least one mutation chosen from a NF1, RAS (including N-, K-, and H-RAS), RAF (including A-, B-, and C-RAF), and MEK (including MEK1 and MEK2) mutation. In some embodiments, the cancer is resistant to treatment with at least one of a proteasome inhibitor or a MEK inhibitor. In some embodiments, the combination therapy produces a synergistic effect.

Claim (Index 9):
The method of  claim 8 , wherein the RAF mutation is in at least codon 600.

Metadata:
- Claim Count in Document: 37.0
- Percentile: 86.0
- Lexical Diversity: 1.98246
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14387735', '13139060', '15011003', '14775009', '13825713']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7923931167423244
- 35 USC 102 Novelty (BERT): 0.5122873327377931
- Combined Prediction Score: 0.7643825383418713
- Mean Citation Score: 259.778738
- Max Citation Score: 278.75934
- Similarity Product: 190.0980468814409

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test